SEC Form ARS filed by Cue Health Inc.
$HLTH
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | Buy → Neutral | BTIG Research | |
| 10/19/2021 | $18.00 | Buy | BTIG Research |
| 10/19/2021 | $12.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $19.00 | Buy | Goldman Sachs |
| 10/19/2021 | $14.00 | Outperform | Cowen & Co. |
For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c